Steven G. Gourlay
Chief Executive Officer at ACTINOGEN MEDICAL LIMITED
Net worth: 1 M $ as of 2024-03-30
Profile
Steven G.
Gourlay is currently the Chief Executive Officer, MD & Director at Actinogen Medical Ltd.
He previously worked as the Senior Director-Clinical & Safety at Genentech, Inc. from 1997 to 2004.
He also held positions as a Director at Applied Physiology Pty Ltd., Verva Pharmaceuticals Ltd., Elastagen Pty Ltd., and Endoluminal Sciences Pty Ltd.
Additionally, he served as the Chief Medical Officer at Principia Biopharma, Inc. from 2013 to 2018.
Dr. Gourlay has also worked as a Faculty Member at Monash University and The University of California, San Francisco.
He was a Partner at GBS Venture Partners Pty Ltd.
Dr. Gourlay holds a doctorate degree from the University of Melbourne and Monash University, as well as an MBA from Macquarie University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-08-02 | 50,350,426 ( 2.16% ) | 1 M $ | 2024-03-30 |
Steven G. Gourlay active positions
Companies | Position | Start |
---|---|---|
ACTINOGEN MEDICAL LIMITED | Chief Executive Officer | 2021-03-14 |
Former positions of Steven G. Gourlay
Companies | Position | End |
---|---|---|
PRINCIPIA BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 2018-10-23 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2003-12-31 |
Verva Pharmaceuticals Ltd.
Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Director/Board Member | - |
Endoluminal Sciences Pty Ltd.
Endoluminal Sciences Pty Ltd. Medical DistributorsDistribution Services Endoluminal Sciences Pty Ltd. develops novel platform technologies for endovascular prostheses. The firm’s focus is to develop the treatment of abdominal aortic aneurysms (AAAs). The company was founded by Ashish Mitra and Martin Ng in 2007 and is headquartered in Sydney, Australia. | Director/Board Member | - |
Elastagen Pty Ltd.
Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Director/Board Member | - |
Training of Steven G. Gourlay
University of Melbourne | Doctorate Degree |
Monash University | Doctorate Degree |
Macquarie University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ACTINOGEN MEDICAL LIMITED | Health Technology |
Private companies | 7 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
GBS Venture Partners Pty Ltd.
GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Finance |
Applied Physiology Pty Ltd.
Applied Physiology Pty Ltd. Medical DistributorsDistribution Services Applied Physiology developed and commercializes guidance devices for use in the critical care environment. Navigator™, the flagship product, focuses on hemodynamic management. Applied Physiology aims to develop products that make life easier for the clinician. The devices continuously acquire physiological data from conventional monitors and use it to create a graphical depiction of the patient position, and continuous advice on the next therapy. Applied Physiology's devices enable the implementation of targeted therapy to optimize care and outcomes. The clinician specifies target ranges for the variables being monitored. The devices graphically display the patient position in relation to these targets, and indicate a course of therapy that will guide the patient to the target area. This self-adaptive protocol facilitates a safe and systematic approach to bedside care, where whole teams work toward a unified goal. Applied Physiology's therapeutic guidance devices have demonstrated potential benefits for both clinicians and patients: Clinical teamwork is enhanced and goals unified, Improved patient put comes, Reduced length of stay and Reduced morbidity in critical care units. At the heart of Applied Physiology's technology are mathematical algorithms based on a combination of systems physiology and control engineering methods. This rigorous basis has enabled the development of sound and reliable patient-specific solutions to treatment planning problems that are often counter-intuitive. Applied Physiology's flagship product Navigator™, which targets pressure and flow in the circulatory system, will be available for sale in Europe and Australia in the second quarter 2010. It will be available for sale in the U.S. pending regulatory approval from the FDA. The company is based Australia, and established European operations in the UK in 2008. | Distribution Services |
Verva Pharmaceuticals Ltd.
Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Health Technology |
Elastagen Pty Ltd.
Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Health Technology |
Endoluminal Sciences Pty Ltd.
Endoluminal Sciences Pty Ltd. Medical DistributorsDistribution Services Endoluminal Sciences Pty Ltd. develops novel platform technologies for endovascular prostheses. The firm’s focus is to develop the treatment of abdominal aortic aneurysms (AAAs). The company was founded by Ashish Mitra and Martin Ng in 2007 and is headquartered in Sydney, Australia. | Distribution Services |
- Stock Market
- Insiders
- Steven G. Gourlay